文献速递免疫规划

孟加拉国成人中两种重组乙型肝炎疫苗(Hepa-B与Engerix-B)的非劣效性试验

A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
PubMed 文献 · Vaccine · 2021-09-22

在孟加拉国达卡开展随机观察者盲法非劣效性临床试验,纳入158名成人,比较本地生产的Hepa-B与WHO预认证的Engerix-B疫苗按0、1、6月程序接种的免疫原性和安全性。Hepa-B组三剂后血清转化率为98.67%,Engerix-B组为100%,各时间点几何均值比均大于预设非劣效界值0.5,常见不良反应为注射部位疼痛且无严重不良事件。结果表明Hepa-B非劣效于Engerix-B。

要点

  • Hepa-B疫苗三剂后血清转化率98.67%,与Engerix-B的100%相近。
  • 所有分析时间点两种疫苗的几何均值比均大于非劣效界值0.5。
  • 最常见不良反应为注射部位疼痛,未报告严重不良事件。

核心结论

  • 本地生产的Hepa-B疫苗对Engerix-B疫苗非劣效。

研究设计与样本

  • 在孟加拉国达卡开展的随机观察者盲法非劣效性临床试验。
  • 共纳入158名合格成人参与者,Hepa-B组平均年龄30岁,Engerix-B组平均年龄29岁。
  • 两种疫苗均按0、1、6月程序肌内注射,并在不同时间点检测基线及接种后抗-HBs滴度。

主要发现

  • Hepa-B疫苗三剂后血清转化率为98.67%,Engerix-B疫苗为100%。
  • 两种疫苗在所有分析时间点的几何均值比均大于预设非劣效界值0.5。
  • 注射部位疼痛是两种疫苗最常见症状,均无并发症自行缓解。
  • 研究期间未报告严重不良事件。

临床怎么用

  • 在成人乙肝疫苗接种中,本地生产的Hepa-B疫苗可作为Engerix-B的非劣效替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Worldwide Hepatitis B is known as one of the imperative causes of mortality and morbidity as well as occupational health hazard among health workers. Bangladesh is intermediate endemic country for Hepatitis B infection for which the government has introduced hepatitis B vaccination into the Expanded Programme on Immunization (EPI) nationwide since 2009 for new born children. However, the people who were born before 2009, was dependent on imported hepatitis B vaccine as there was no locally manufactured hepatitis B vaccine in Bangladesh. Hence, we conducted a randomized observer blinded non-inferiority clinical trial to assess the immunogenicity and safety of the locally manufactured Hepa-B vaccine in comparison with World Health Organization prequalified Engerix-B vaccine. Total 158 eligible adult participants were enrolled in this study with mean age of 30 and 29 years old in Hepa-B and Engerix-B groups, respectively. Both the vaccines were administered intramuscularly at 0, 1 and 6 months schedule. Baseline and post vaccination anti-HBs titers were measure at different time points. Seroconversion rate post three doses of Hepa-B vaccine was 98.67% similar to the comparator Engerix-B vaccine which was 100%. The geometric mean test ratios of both vaccines at all analysis time points were found > 0.5 predefined non-inferiority margin. Soreness at the injection site was the most common symptom for both the vaccines which resolved without any complication. No serious adverse event was reported throughout the study period. These results suggest that locally manufactured hepatitis B vaccine 'Hepa-B' vaccine is non-inferior to the well-known licensed 'Engerix-B' vaccine. ClinicalTrials.gov NCT03627507.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chowdhury F, Akter A, Rahman Bhuiyan T, et al. A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh. Vaccine. 2021. PMID: 34561142. doi:10.1016/j.vaccine.2021.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。